Evidence map›Paper›PMID 31092013›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2019

MicroRNA-615-5p Regulates Angiogenesis and Tissue Repair by Targeting AKT/eNOS (Protein Kinase B/Endothelial Nitric Oxide Synthase) Signaling in Endothelial Cells.

Basak Icli, Winona Wu, Denizhan Ozdemir, Hao Li, Henry S Cheng, Stefan Haemmig, Xin Liu, Giorgio Giatsidis, Seyma Nazli Avci, Nathan Lee and 10 more

Open access · greenAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. MicroRNAs as Regulators of Radiation-Induced Oxidative Stress.Current issues in molecular biology · 2024
    Review
  13. MicroRNA-409-3p/BTG2 signaling axis improves impaired angiogenesis and wound healing in obese mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Basak IcliFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Winona WuFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Denizhan OzdemirFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Hao LiFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Henry S ChengFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Stefan HaemmigFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Xin LiuFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Giorgio GiatsidisDivision of Plastic Surgery, Department of Surgery (G.G., D.P.O.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Seyma Nazli AvciFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Nathan LeeFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Raphael Boesch GuimaraesInstituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia (ICFUC), Porto Alegre, RS, Brazil (B.G., A.M.).
Andre ManicaInstituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia (ICFUC), Porto Alegre, RS, Brazil (B.G., A.M.).
Julio F MarchiniHeart Institute, University of São Paulo Medical School, Brazil (J.F.M.).
Stein Erik RynningDepartment of Cardiac Surgery, LHL Hospital Gardermoen, Jessheim, Norway (S.E.R., I.R.).
Ivar RisnesDepartment of Cardiac Surgery, LHL Hospital Gardermoen, Jessheim, Norway (S.E.R., I.R.).
Ivana HollanFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Kevin CroceFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Xianbin YangAM Biotechnologies, LLC, Houston, TX (X.Y.).
Dennis P OrgillDivision of Plastic Surgery, Department of Surgery (G.G., D.P.O.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Mark W FeinbergFrom the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Brigham and Women's Hospital · USHarvard University · USFundação Universitária de Cardiologia · BRUniversidade de São Paulo · BR

Funding

STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WAYNE I LENCER · 1986 to 2026
$32.4M
MiR-181b, endothelial cells, and vascular inflammationR01HL115141 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2012 to 2024
$6.8M
miR-615, AKT/eNOS signaling, and angiogenesisR01HL148207 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2020 to 2023
$2.6M
MicroRNA-181b and SepsisR01GM115605 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BARON, REBECCA M, FEINBERG, MARK W · 2015 to 2018
$1.8M
KLF10, CD4+ T cells, and transplant arteriopathyR01HL134849 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2017 to 2020
$1.7M
MiR-26a, endothelial cells, and neovascularizationR01HL117994 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2013 to 2016
$1.6M
NHLBI NIH HHS R01 HL115141NHLBI NIH HHS R01 HL117994NHLBI NIH HHS R01 HL134849NHLBI NIH HHS R01 HL148207NIDDK NIH HHS P30 DK034854NIGMS NIH HHS R01 GM115605
6 · The paper itself

Abstract

Objective- In response to tissue injury, the appropriate progression of events in angiogenesis is controlled by a careful balance between pro and antiangiogenic factors. We aimed to identify and characterize microRNAs that regulate angiogenesis in response to tissue injury. Approach and Results- We show that in response to tissue injury, microRNA-615-5p (miR-615-5p) is rapidly induced and serves as an antiangiogenic microRNA by targeting endothelial cell VEGF (vascular endothelial growth factor)-AKT (protein kinase B)/eNOS (endothelial nitric oxide synthase) signaling in vitro and in vivo. MiR-615-5p expression is increased in wounds of diabetic db/db mice, in plasma of human subjects with acute coronary syndromes, and in plasma and skin of human subjects with diabetes mellitus. Ectopic expression of miR-615-5p markedly inhibited endothelial cell proliferation, migration, network tube formation in Matrigel, and the release of nitric oxide, whereas miR-615-5p neutralization had the opposite effects. Mechanistic studies using transcriptomic profiling, bioinformatics, 3' untranslated region reporter and microribonucleoprotein immunoprecipitation assays, and small interfering RNA dependency studies demonstrate that miR-615-5p inhibits the VEGF-AKT/eNOS signaling pathway in endothelial cells by targeting IGF2 (insulin-like growth factor 2) and RASSF2 (Ras-associating domain family member 2). Local delivery of miR-615-5p inhibitors, markedly increased angiogenesis, granulation tissue thickness, and wound closure rates in db/db mice, whereas miR-615-5p mimics impaired these effects. Systemic miR-615-5p neutralization improved skeletal muscle perfusion and angiogenesis after hindlimb ischemia in db/db mice. Finally, modulation of miR-615-5p expression dynamically regulated VEGF-induced AKT signaling and angiogenesis in human skin organoids as a model of tissue injury. Conclusions- These findings establish miR-615-5p as an inhibitor of VEGF-AKT/eNOS-mediated endothelial cell angiogenic responses and that manipulating miR-615-5p expression could provide a new target for angiogenic therapy in response to tissue injury. Visual Overview- An online visual overview is available for this article.

Indexed as

Neovascularization, PhysiologicAnimalsEndothelial CellsHumansMaleMiceMice, Inbred C57BLMicroRNAsNitric Oxide Synthase Type IIIPhosphorylationProto-Oncogene Proteins c-aktSignal TransductionTumor Suppressor ProteinsVascular Endothelial Growth Factor AMicroRNAsMIRN615 microRNA, humanNitric Oxide Synthase Type IIIProto-Oncogene Proteins c-aktRASSF2 protein, humanTumor Suppressor ProteinsVascular Endothelial Growth Factor AAKT/eNOS signalingangiogenesisendothelial cellsmicroRNAstissue repair

Identifiers

PMID31092013
PMCPMC6594892
OpenAlexW2945726720

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.